GoodRx Holdings (GDRX) | Financial Analysis & Statements
GoodRx Holdings Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
194.8M
Gross Profit
177.3M
91.03%
Operating Income
22.7M
11.65%
Net Income
5.4M
2.79%
EPS (Diluted)
$0.02
Balance Sheet Metrics
Total Assets
1.4B
Total Liabilities
787.8M
Shareholders Equity
616.3M
Debt to Equity
1.28
Cash Flow Metrics
Operating Cash Flow
134.5M
Free Cash Flow
17.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
GoodRx Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 796.9M | 792.3M | 750.3M | 766.6M | 745.4M |
| Cost of Goods Sold | 57.6M | 48.2M | 66.9M | 65.1M | 46.7M |
| Gross Profit | 739.3M | 744.1M | 683.3M | 701.5M | 698.7M |
| Gross Margin % | 92.8% | 93.9% | 91.1% | 91.5% | 93.7% |
| Operating Expenses | |||||
| Research & Development | 121.0M | 123.7M | 135.8M | 143.1M | 125.9M |
| Selling, General & Administrative | 445.5M | 485.0M | 466.8M | 502.4M | 524.9M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 566.5M | 608.7M | 602.7M | 645.6M | 650.8M |
| Operating Income | 87.5M | 65.8M | -27.0M | 1.7M | 13.4M |
| Operating Margin % | 11.0% | 8.3% | -3.6% | 0.2% | 1.8% |
| Non-Operating Items | |||||
| Interest Income | 10.9M | 23.3M | 32.2M | 9.3M | 59.0K |
| Interest Expense | 42.6M | 52.9M | 56.7M | 34.2M | 23.6M |
| Other Non-Operating Income | 718.0K | -4.7M | -4.0M | - | - |
| Pre-tax Income | 56.5M | 31.5M | -55.6M | -23.2M | -10.2M |
| Income Tax | 26.1M | 15.1M | -46.7M | 9.6M | 15.1M |
| Effective Tax Rate % | 46.2% | 47.9% | 0.0% | 0.0% | 0.0% |
| Net Income | 30.4M | 16.4M | -8.9M | -32.8M | -25.3M |
| Net Margin % | 3.8% | 2.1% | -1.2% | -4.3% | -3.4% |
| Key Metrics | |||||
| EBITDA | 184.4M | 156.0M | 108.8M | 65.2M | 48.0M |
| EPS (Basic) | $0.09 | $0.04 | $-0.02 | $-0.08 | $-0.06 |
| EPS (Diluted) | $0.09 | $0.04 | $-0.02 | $-0.08 | $-0.06 |
| Basic Shares Outstanding | 356327000 | 385737000 | 410315000 | 412858000 | 409981000 |
| Diluted Shares Outstanding | 356327000 | 385737000 | 410315000 | 412858000 | 409981000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
GoodRx Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 261.8M | 448.3M | 672.3M | 757.2M | 941.1M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 235.7M | 145.9M | 143.6M | 117.1M | 118.1M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 126.4M | 50.1M | 40.4M | 35.1M | 21.3M |
| Total Current Assets | 643.1M | 659.3M | 872.8M | 919.7M | 1.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 28.8M | 27.8M | 29.9M | 35.9M | 27.7M |
| Goodwill | 1.1B | 998.4M | 977.9M | 1.0B | 793.2M |
| Intangible Assets | 203.3M | 176.9M | 156.3M | 189.9M | 133.8M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 86.2M | 100.7M | 103.0M | 27.2M | 6.0M |
| Total Non-Current Assets | 761.0M | 728.8M | 716.0M | 684.9M | 518.8M |
| Total Assets | 1.4B | 1.4B | 1.6B | 1.6B | 1.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 19.4M | 14.1M | 36.3M | 17.7M | 17.5M |
| Short-term Debt | 9.8M | 10.6M | 15.0M | 11.1M | 12.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 130.1M | 15.8M | - | - | - |
| Total Current Liabilities | 246.0M | 123.9M | 122.6M | 76.3M | 81.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 533.1M | 532.8M | 696.1M | 705.9M | 689.4M |
| Deferred Tax Liabilities | - | - | - | - | 244.0K |
| Other Non-Current Liabilities | 8.7M | 6.8M | 8.2M | 7.6M | 5.4M |
| Total Non-Current Liabilities | 541.8M | 539.5M | 704.3M | 713.5M | 694.8M |
| Total Liabilities | 787.8M | 663.4M | 826.8M | 789.8M | 775.9M |
| Equity | |||||
| Common Stock | 34.0K | 38.0K | 40.0K | 40.0K | 40.0K |
| Retained Earnings | -1.4B | -1.4B | -1.5B | -1.4B | -1.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 616.3M | 724.7M | 762.0M | 814.8M | 831.7M |
| Key Metrics | |||||
| Total Debt | 542.8M | 543.4M | 711.1M | 717.0M | 702.3M |
| Working Capital | 397.1M | 535.4M | 750.2M | 843.4M | 1.0B |
Balance Sheet Composition
GoodRx Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 30.4M | 16.4M | -8.9M | -32.8M | -25.3M |
| Depreciation & Amortization | 85.2M | 69.5M | 107.7M | 54.2M | 34.5M |
| Stock-Based Compensation | 76.6M | 99.0M | 104.8M | 120.2M | 160.5M |
| Working Capital Changes | -49.2M | -29.9M | -11.0M | -1.4M | -42.9M |
| Operating Cash Flow | 170.7M | 149.8M | 139.9M | 164.5M | 146.3M |
| Investing Activities | |||||
| Capital Expenditures | -3.5M | -1.2M | -1.0M | -4.0M | -4.6M |
| Acquisitions | -43.4M | 0 | 0 | -155.3M | -144.3M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -49.5M | -1.2M | -1.0M | -159.3M | -148.8M |
| Financing Activities | |||||
| Share Repurchases | -216.4M | -158.8M | -104.0M | -101.7M | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 472.0M | - | 0 | 0 |
| Debt Repayment | -5.0M | -639.0M | -5.3M | -7.0M | -7.0M |
| Financing Cash Flow | -235.8M | -358.3M | -174.7M | -129.4M | -65.5M |
| Free Cash Flow | 93.9M | 113.5M | 82.5M | 91.6M | 144.3M |
| Net Change in Cash | -114.6M | -209.8M | -35.9M | -124.1M | -68.1M |
Cash Flow Trend
GoodRx Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.67
Forward P/E
6.29
Price to Book
1.28
Price to Sales
0.99
PEG Ratio
6.29
Profitability Ratios
Profit Margin
3.82%
Operating Margin
18.98%
Return on Equity
4.54%
Return on Assets
4.75%
Financial Health
Current Ratio
2.61
Debt to Equity
88.08
Beta
1.47
Per Share Data
EPS (TTM)
$0.09
Book Value per Share
$1.81
Revenue per Share
$2.24
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GDRX | 787.9M | 25.67 | 1.28 | 4.54% | 3.82% | 88.08 |
| Ge Healthcare | 31.9B | 15.92 | 3.18 | 22.38% | 10.10% | 98.72 |
| Veeva Systems | 26.5B | 29.57 | 3.66 | 13.93% | 28.45% | 1.33 |
| Omnicell | 1.7B | 918.75 | 1.34 | 0.17% | 0.17% | 16.59 |
| Teladoc Health | 1.0B | - | 0.74 | -13.93% | -7.92% | 75.06 |
| Certara | 969.0M | 105.00 | 0.95 | -0.15% | -0.38% | 28.96 |
Financial data is updated regularly. All figures are in the company's reporting currency.






